Placeholder

Standardized Development Metrics

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1648. Category: .

Product Description

Imagine the confusion if every Major League Baseball team had its own way of calculating batting averages. This fictional scenario is analogous to the real environment in which sponsors and CROs are currently operating.
With every company — sponsors and CROs — having its own set of metrics and tracking methods for clinical trials, across-the-board analyses and comparisons are major challenges. Metrics are crucial to keeping clinical trials on track and identifying weak spots that may impede success, but only a fraction of the industry currently uses standardized performance metrics, says Linda Sullivan, VP of operations at Metrics Champion Consortium (MCC). The nonprofit organization aims to develop performance metrics within the biotechnology and pharmaceutical industry that will enhance performance, effectiveness, and efficiency, and set appropriate levels of controls for both sponsors and service providers.
These MCC Clinical Trial metrics are the fourth set of standards that the organization is initiating; it has also addressed laboratory performance, ECG performance…

Sidebar:
MCC Identified Metrics
Building Partnerships Around Standardized
Performance Metrics
MCC Participating Organizations
Metrics Development Process
Demand for Performance Metrics

Related Podcast: Redefining the CRO

Experts

Malcolm Bohm. President, Trialytics, a site selection and patient recruitment company specializing in applying advanced analytics of healthcare data to clinical-development strategies to optimize protocol designs, mitigate the risks of site selection, locate the right patients, and drive patient recruitment at the local level through primary-care pathways. For more information, visit trialytics.com.
Gavin R. Corcoran, M.D., FACP. Chief Scientific Officer, Stiefel Laboratories Inc., which is committed to advancing dermatology and skin science around the world. For more information, visit stiefel.com.
Gregg Dearhammer. President, i3 Statprobe, a global pharmaceutical services company that provides integrated strategies and solutions throughout the product life cycle. For more information, visit i3global.com.
Jeff Kueffer. VP, Global Operations Management, INC Research, a therapeutically focused CRO. For more information, visit incresearch.com.
Sharon Moore, M.D., MPH, MBA. Global Head, Quality Assurance, Chiltern International Inc., a global CRO with experience in conducting and staffing global Phase I to Phase V trials. For more information, visit chiltern.com.
Linda Sullivan. VP, Operations, The Metrics Champion Consortium, an open, multidisciplinary, nonprofit organization comprised of biotechnology, pharmaceutical, and service provider organizations. For more information, visit metricschampion.org.
Mark Wade. Global Practice Leader, Life Sciences, Lionbridge, a provider of globalization, development, and testing services. For more information, visit lionbridge.com.

FEEDBACK